Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients ...

Rates of pancreatic adenocarcinoma increased significantly among younger individuals than older ones. Colorectal adenocarcinoma diagnoses also have increased among patients aged 15 to 34 years.

Increase seen across age groups, while incidence of colorectal adenocarcinoma increased most in those aged 15 to 34 years.

WEDNESDAY, April 23, 2025 (HealthDay News) -- From 2000 to 2021, there was an increase in the incidence of pancreatic adenocarcinoma, which was seen in all age groups, according to a study ...

Pancreatic cancer is a malignancy with poor prognosis and overall poor response to systemic therapy. Moreover, patients with locally advanced or unresectable tumours have historically worse outcomes ...

There has been a sharp increase in colorectal and pancreatic cancer rates among Americans under 55 years, despite declines in older adults, according to a new study.

The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.

Bizengri received FDA approval for NSCLC and pancreatic adenocarcinoma with NRG1 gene fusion after prior therapy failure. The eNRGy study showed a 33% ORR in NSCLC and 40% in pancreatic adenocarcinoma ...

November is Pancreatic Cancer Awareness Month.The observance is intended to raise awareness about the disease and the need for more effective therapies.

Immunohistochemistry revealed that the neoplastic glands were positive for pan-cytokeratin, confirming the pancreatic epithelial origin of the tumor. This is the first report of sclerosing ...